Posted on

Mindset Pharma Announces Closing of $7.5 Million Bought Deal Public Offering

Toronto, Ontario–(Newsfile Corp. – April 15, 2021) – Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) (“Mindset” or the “Company“) is pleased to announce that it has completed the previously announced “bought deal” public offering through the issuance of an aggregate of 10,000,000 units (each, a “Unit“) of the Company at a price of $0.75 per Unit (the “Issue Price“) for aggregate gross proceeds to the Company of $7,500,000 (the “Offering“). The Units were issued and sold pursuant to the terms of an underwriting agreement dated March 25, 2021, among the Company, Canaccord Genuity Corp. (the “Lead Underwriter“), as lead underwriter and sole bookrunner, along with Stifel Nicolaus Canada Inc. and Cormark Securities Inc. (collectively with the Lead Underwriter, the “Underwriters“).

Each Unit consists of one common share of the Company (each, a “Unit Share“) and one common share purchase warrant of the Company (each, a “Warrant“). Each Warrant will entitle the holder thereof to purchase one common share of the Company (each, a “Warrant Share“) at an exercise price of $1.10 per Warrant Share at any time until 5:00 p.m. (Toronto time) on the date that is 36 months following the closing date of the Offering (the “Closing Date“), subject to adjustment in certain events and subject to the terms of a warrant indenture (the “Warrant Indenture“) dated April 15, 2021 between the Company and Computershare Investor Services Inc., as warrant agent.

In addition, the Company has applied to list the Warrants issued in connection with the Offering on the Canadian Securities Exchange (“CSE“) under the symbol “MSET.WT”. The Company anticipates that the Warrants will commence trading on the CSE at the open of market on or about Friday, April 17, 2021. The listing of the Warrants on the CSE remains subject to receipt of all necessary regulatory approvals, including the approval of the CSE.

The Company has granted the Underwriters an option (the “Over-Allotment Option“) to purchase up to an additional 1,500,000 Units (the “Over-Allotment Units“) at the Issue Price, to cover over-allotments, if any, and for market stabilization purposes. The Over-Allotment Option is exercisable at any time, in whole or in part, for a period of thirty (30) days after and including the Closing Date, which, if exercised in full, would result in additional gross proceeds of $1,125,000 to the Company.

In respect of the Offering, the Units (including the Over-Allotment Units issuable upon exercise of the Over-Allotment Option, as applicable) were offered by way of a short form prospectus dated April 12, 2021 filed in all of the provinces of Canada, except Québec.

As consideration for their services to be provided in connection with the Offering, the Underwriters received a cash commission equal to 7.0% of the gross proceeds of the Offering and such number of broker warrants of the Company (the “Underwriters’ Warrants“) as is equal to 7.0% of the number of Units sold pursuant to the Offering. Each Underwriters’ Warrant entitles the holder thereof to acquire one Unit at the Issue Price for a period of thirty-six (36) months from the Closing Date.

The net proceeds of the Offering will be used for the expansion of Mindset’s current pipeline of propriety compounds, further pre-clinical testing of its current compounds, advancement of Mindset’s psilocybin synthesis process, formulation development chemistry and for general working capital purposes.

The securities offered have not been registered under the U.S. Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in any jurisdiction in which such offer, solicitation or sale would be unlawful.

FOR MORE INFORMATION, PLEASE CONTACT:

James Lanthier
Chief Executive Officer
jlanthier@mindsetpharma.com

Jason Atkinson
VP, Corporate Development
jatkinson@mindsetpharma.com
647-938-5266

About Mindset Pharma Inc.

Mindset Pharma Inc. is a drug discovery and development company focused on creating optimized and patentable next-generation psychedelic medicines to treat neurological and psychiatric disorders with unmet needs. Mindset was established to develop next generation pharmaceutical assets that leverage the breakthrough therapeutic potential of psychedelic drugs. Mindset is developing several novel families of next generation psychedelic compounds, as well as an innovative process to chemically synthesize psilocybin along with its own proprietary compounds. www.mindsetpharma.com

Forward-Looking Information

This news release contains statements and information that, to the extent that they are not historical fact, may constitute “forward-looking information” within the meaning of applicable securities legislation. Forward-looking information is typically, but not always, identified by the use of words such as “will”, “intends”, “scheduled”, “to be” and “may be” and similar words, including negatives thereof, or other similar expressions concerning matters that are not historical facts. Forward-looking information in this news release includes, but is not limited to, statements regarding: the filing of the short form prospectus in each of the provinces of Canada (except Québec); the completion of the Offering, the intended use of the net proceeds therefrom, and the anticipated closing date thereof; that the Units may be offered in jurisdictions outside of Canada. Such forward-looking information is based on various assumptions and factors that may prove to be incorrect, including, but not limited to, factors and assumptions with respect to: the receipt of all necessary regulatory and other approvals or consents; the ability of the Company to successfully implement its strategic plans and initiatives and whether such strategic plans and initiatives will yield the expected benefits; approvals and authorizations from regulatory authorities, and the timing thereof. Although the Company believes that the assumptions and factors on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because the Company can give no assurance that it will prove to be correct or that any of the events anticipated by such forward-looking information will transpire or occur, or if any of them do so, what benefits the Company will derive there from. Actual results could differ materially from those currently anticipated due to a number of factors and risks including, but not limited to: conditions in the psychedelic pharmaceutical industry; fluctuations in market conditions, including in securities markets; economic factors; the ability of management to execute its business strategy, objectives and plans; and the impact of general economic conditions and the COVID-19 pandemic in Canada. Additional information regarding risks and uncertainties relating to the Company’s business are contained under the heading “Risk Factors” in the Company’s annual information form for the financial year ended June 30, 2020 dated March 5, 2021. The forward-looking information included in this news release is made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking information to reflect new information, subsequent events or otherwise, except as required by applicable law.

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES.

‍

Posted on

MINDCURE Announces Partnership with Speak Ai to Enhance iSTRYM, the Company’s Psychedelic Digital Therapeutics Technology Platform

Utilizing Speak Ai’s technology, iSTRYM will provide Ai-driven intelligence to help therapists identify the most efficient and efficacious outcomes for patients of psychedelic assisted psychotherapy

VANCOUVER, BC, April 13, 2021 /CNW/ – Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) (“MINDCURE” or the “Company”) a leader in advanced proprietary technology for psychedelic therapy, is pleased to announce that it has entered into a partnership with Speak Ai Inc. (“Speak Ai”). The Canadian-based technology company helps individuals and organizations analyze media, language, and metadata to automatically generate valuable insights through machine learning. MINDCURE will be integrating the platform’s capabilities into iSTRYM, and will also work with Speak Ai to develop proprietary, technology-based mental health solutions.

By combining audio, video, and text analysis with metadata in a single platform, Speak Ai has developed a comprehensive solution for generating personalized insights to improve research and personal wellbeing. Their technology has been honed over several years of development, research, and experience, and the organization has built a strong reputation within the psychedelic community.

“We are proud to partner with MINDCURE today to help build iSTRYM into a powerful solution for therapists and patients around the world,” said Tyler Bryden, Speak Ai Founder. “I have had the privilege to witness the potential of psychedelic-assisted therapies in my own life and in the lives of amazing people around me who are healing from anxiety, depression, PTSD, traumatic brain injuries, and more.”

This partnership will result in driving data for iSTRYM, taking unstructured data, and creating structure and metrics for the platform integration. Natural language processing with machine learning allows MINDCURE to drive insights for the therapist and patient. This information is often difficult to capture using traditional methods during the course of therapy.

“By developing solutions with empathy, we can improve the level of care to help people avoid, navigate through and recover from crises. We share the belief with MINDCURE that technology can play a major role in enabling these potentially life-changing and individual therapies to succeed at scale,” continued Bryden.

“We are excited to work with Tyler and the team at Speak Ai because of their intimate knowledge of the value of technology in the therapeutic and integration process within psychedelics and the traditional therapeutic model,” said MINDCURE CEO and President Kelsey Ramsden. “We will be building custom integrations with Speak Ai for the iSTRYM platform that allow us to marry sentiment with biometric data, location, weather, and a variety of other variables to help optimize our integration protocols and provide individuals with quantified care at scale globally, all with the stated goal of advancing Mental Wealth, rooted in data.”

About Speak Ai Inc.

Speak Ai is a technology company harnessing the power of AI to help individuals and organizations transform their media into incredible assets for growth. By combining audio, video, and text analysis with metadata in a single platform, the Speak Ai team has developed a comprehensive solution for generating personalized insights that improves research and wellbeing.

Speak Ai works with well-established organizations like the London Health Sciences Centre and Ryerson University to improve recording systems, create transcripts, analyze audio and video quicker and less expensively, and provide an interactive media interface to easily navigate through long recordings. One of the researchers from LHSC said: “This is a complete paradigm shift for how we do research.”

About Mind Cure Health (MINDCURE) Inc.

MINDCURE exists as a response to the current mental health crisis and urgent calls for effective treatments. MINDCURE believes in the need to reinvent the mental health care model for patients and practitioners to allow psychedelics to advance into common and accepted care.

MINDCURE is focused on identifying and developing pathways and products that ease suffering, increase productivity, and enhance mental health. MINDCURE is interested in exploring diverse therapeutic areas beyond psychiatry, including digital therapeutics, neuro-supports, and psychedelics, all to improve mental health.

On Behalf of the Board of Directors
Kelsey Ramsden, President & CEO
Phone: 1-888-593-8995

Forward-Looking Information

Certain statements in this news release may constitute “forward-looking information” within the meaning of applicable securities laws (also known as forward-looking statements). Forward-looking information involves known and unknown risks, uncertainties and other factors, and may cause actual results, performance or achievements or industry results, to be materially different from any future results, performance or achievements or industry results expressed or implied by such forward-looking information. Forward-looking information generally can be identified by the use of terms and phrases such as “anticipate”, “believe”, “could”, “estimate”, “expect”, “feel”, “intend”, “may”, “plan”, “predict”, “project”, “subject to”, “will”, “would”, and similar terms and phrases, including references to assumptions. Some of the specific forward-looking information in this news release includes, but is not limited to, statements with respect to: Speak Ai developing proprietary mental health technology-based solutions for MINDCURE; iSTRYM becoming a must-have solution for therapists and patients around the world; this partnership driving data for iSTRYM; MINDCURE significantly improving the level of care, help people avoid and recover from crises and enable them to reach their fullest potential; and MINDCURE advancing Mental Wealth, rooted in data.

Forward-looking information is based on a number of key expectations and assumptions made by MINDCURE, including, without limitation: the COVID-19 pandemic impact on the Canadian economy and MINDCURE’s business, and the extent and duration of such impact; no change to laws or regulations that negatively affect MINDCURE’s business; there will be a demand for MINDCURE’s products in the future; no unanticipated expenses or costs arise; MINDCURE will be able to continue to identify products that make them ideal candidates for providing solutions for treating mental health; that the functional mushroom industry will continue to grow; Speak Ai will develop proprietary mental health technology-based solutions for MINDCURE; iSTRYM will become a must-have solution for therapists and patients around the world; and MINDCURE will be able to operate its business as planned. Although the forward-looking information contained in this news release is based upon what MINDCURE believes to be reasonable assumptions, it cannot assure investors that actual results will be consistent with such information.

Forward-looking information is provided for the purpose of presenting information about management’s current expectations and plans relating to the future and readers are cautioned that such statements may not be appropriate for other purposes. Forward-looking information involves significant risks and uncertainties and should not be read as a guarantee of future performance or results as actual results may differ materially from those expressed or implied in such forward-looking information. Those risks and uncertainties include, among other things, risks related to: the impacts of the COVID-19 pandemic on the Canadian economy, MINDCURE’s industry and MINDCURE’s business, which may negatively impact, and may continue to negatively impact, MINDCURE and may materially adversely affect MINDCURE’s investments, results of operations, financial condition, and MINDCURE’s ability to obtain additional equity or debt financing, and satisfy its financial obligations; general economic conditions; future growth potential; competition for mental health and wellness investments; Speak Ai may not develop proprietary mental health technology-based solutions for MINDCURE; iSTRYM may not become a must-have solution for therapists and patients around the world; and changes in legislation or regulations. Management believes that the expectations reflected in the forward-looking information contained herein are based upon reasonable assumptions and information currently available; however, management can give no assurance that actual results will be consistent with such forward-looking information. Additional information on the risk factors that could affect MINDCURE can be found under “Risk Factors” in MINDCURE’s final prospectus which is available on SEDAR at www.sedar.com.

The forward-looking information contained herein is expressly qualified in its entirety by this cautionary statement. Forward-looking information reflects management’s current beliefs and is based on information currently available to MINDCURE. The forward-looking information is stated as of the date of this news release and MINDCURE assumes no obligation to update or revise such information to reflect new events or circumstances, except as may be required by applicable law.

The CSE has neither approved nor disapproved the contents of this press release and the CSE does not accept responsibility for the adequacy or accuracy of this release.

SOURCE Mind Cure Health Inc.

For further information: Connect: Investor Relations: investors@mindcure.com; 1-888-593-8995; Jonathan L. Robinson CFA, Partner, Oak Hill Financial Inc., jrobinson@oakhillfinancial.ca, 416-669-1001

Posted on

BETTER PLANT’S JUSU LAUNCHES TWELVE NATURAL HAIR AND BODY CARE PRODUCTS

Vancouver, B.C. – April 8, 2021: Better Plant Sciences Inc. (CSE: PLNT) (OTCQB: VEGGF) (FSE: YG3) (“Better Plant” or the “Company”) a wellness company that develops and sells sustainable, plant-based products, is pleased to announce the launch of a complete line of hair care and body care products from Jusu Wellness Inc. (“Jusu”). The line includes two shampoos, two conditioners, and three body washes. Jusu products are made with natural, non-toxic, sulphate-free ingredients. Jusu has also launched two new hair care gift sets which include shampoo, conditioner, hair putty and hair treatment. Products are available for purchase Worldwide from getjusu.com.

“There is a growing awareness and increasing demand for natural hair care products.” said Penny White, President and CEO of Better Plant. “Jusu Hair products have ingredients like oat protein and Vitamin B5 to nourish the scalp and promote healthy hair growth.”

Jusu skincare products are developed by Green Cosmetic Formulator, Chartered Herbalist and Certified Natural Perfumer, Karen Van Dyck. Her focus with Jusu products is to use food-grade, non-toxic ingredients that cleanse, nourish, hydrate, and protect the body with the power of nature. The hair products are formulated without surfactants and silicone which can help restore hair’s natural oil balance and does not have a negative impact on the environment during the manufacturing process. These twelve new products will finalize Jusu Wellness’s product launches for 2021. The Company’s research and development efforts will focus on optimizing the quality of existing Jusu products based on first-hand consumer feedback and market research.

According to a report by Grand View Research, the global natural hair care product market size was valued at USD 8.74 billion in 2019 and is expected to grow at a compound annual growth rate of 4.7% from 2020 to 2027. Rising awareness related to the benefits of natural hair care products is one of the key factors fueling market growth.

 

About Jusu

Jusu Wellness Inc. and Jusu Bars Corp. are wholly owned subsidiaries of Better Plant and they own and operate Jusu, a full spectrum wellness brand with a mission to enlighten consumers to the protective and effective properties of plant-based products. Jusu is committed to making pure, organic, plant-based products for consumption, home, and personal care.   This includes one JUSU Bar location, a quick serve restaurant alternative in Victoria, BC, as well as an extensive direct-to-consumer product offering including cold-pressed juices, skin care and body products, and a home cleaning line. Jusu is fully dedicated to offering consumers healthier alternatives to currently available chemical-based products.

To purchase Jusu Wellness products visit getjusu.com or follow @jusu on Instagram.

To purchase Jusu juices visit jusubar.com, or follow @jusubars, @jusubarvictoria, or @jusubarcalgary on Instagram.

Use the code MAINSQUEEZE for 10% off all juice orders from jusubars.com from now until April 30th.

 

About Better Plant Sciences Inc.

Better Plant harnesses plant intelligence and leverages modern science to offer sustainable, plant-based products that are better for health and better for the earth. It makes and sells over 90 proprietary products, all made with 100% natural ingredients, under the brands Jusu, Urban Juve and Wright & Well.  It has a direct-to-consumer platform for refrigerated goods that offers easy online ordering and convenient home delivery in select cities in Alberta and BC. Better Plant operates Jusu Bar, a quick serve restaurant alternative in Victoria, BC, which serves up fresh, healthy, and nutritious options with a focus on Jusu cold-pressed juices. Jusubar.com offers home delivery of refrigerated plant-based beverages consisting of cold-pressed juices and packaged juice cleanses. Through its Shopify enabled eCommerce sites getjusu.com and urbanjuve.com, Better Plant sells plant-based personal care products, including skin care, hair care, body care and baby care. Jusu also has a line of plant-based all-natural home cleaning products that are sold to cleaning companies, retailers and sold directly to consumers.  Better Plant also offers operational, financial, and other services to companies with businesses that align with Better Plant’s mission to help create a better world. Better Plant incubated NeonMind, which sells medicinal mushroom infused coffees and is developing drugs with psychedelic ingredients to treat obesity and to suppress appetite. Better Plant owns approximately 27% of NeonMind, which trades separately as a public company under the tickers CSE:NEON and OTC:NMDBF.

For more information on Better Plant, visit betterplantsciences.com or follow @betterplantsciences on Instagram.

 

Penny White, President & CEO

penny@betterplantsciences.com

1-833-515-2677

 

Investor Relations:

Alexandra Dumanski

invest@betterplantsciences.com

1-833-515-2677

 

Sales Inquiries:

Amber Allen, Head of Sales

amber@betterplantsciences.com

604-808-8118

 

The Canadian Securities Exchange has not reviewed, approved or disapproved the contents of this news release.

Cautionary Statement Regarding Forward-Looking Statements

This press release includes forward-looking information and statements (collectively, “forward looking statements”) under applicable Canadian securities legislation.  Forward-looking statements are necessarily based upon a number of estimates, forecasts, beliefs and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause actual results and future events to differ materially from those expressed or implied by such forward-looking statements.  Such risks, uncertainties and factors include, but are not limited to: risks related to the development, testing, licensing, brand development, availability of packaging, intellectual property protection, reduced global commerce and reduced access to raw materials and other supplies due to the spread of COVID-19, the potential for not acquiring any rights as a result of the patent  application and any products making use of the intellectual property may be ineffective or the company may be unsuccessful in commercializing them; and other approvals will be required before commercial exploitation of the intellectual property can happen.  Demand for the company’s products, general business, economic, competitive, political and social uncertainties, delay or failure to receive board or regulatory approvals where applicable, and the state of the capital markets.  Better Plant cautions readers not to place undue reliance on forward-looking statements provided by Better Plant, as such forward-looking statements are not a guarantee of future results or performance and actual results may differ materially. The forward-looking statements contained in this press release are made as of the date of this press release, and Better Plant expressly disclaims any obligation to update or alter statements containing any forward-looking information, or the factors or assumptions underlying them, whether as a result of new information, future events or otherwise, except as required by law.

Posted on

MINDCURE Announces Additional Equity Investment in ATMA, The First Government Approved Psychedelic Journey Centers In Canada; MCUR President and CEO, Kelsey Ramsden Named to ATMA Board of Directors

ATMA Was The First Private Sector Service Provider In Canada Conducting Legal Psychedelic-Assisted Therapy For A Palliative Care Patient Under The Approval Of Health Canada’s Section 56(1) Exemption

VANCOUVER, BC, April 8, 2021 /CNW/ – Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) (“MINDCURE” or the “Company”) a leader in advanced proprietary technology for psychedelic therapy, is pleased to announce a further strategic equity investment in ATMA Journey Centers Inc. (“ATMA“). This follow-on investment enables MINDCURE to retain its 13% ownership of ATMA, in accordance with the terms of the letter of intent (the “LOI“) announced on January 12, 2021. Additionally, MINDCURE President and CEO Kelsey Ramsden will be joining the ATMA Board of Directors.

“We are extremely excited to strengthen our partnership with the team at ATMA through this investment. This further solidifies the Company’s strategic position in clinics and partnerships for the deployment of digital therapeutics to drive near-term revenues. ATMA’s team is a true pioneer in the psychedelic therapy industry by growing a global network of group and retreat psychedelic therapy clinics,” said Kelsey Ramsden, President and CEO, MINDCURE. “ATMA’s established clinical footprint gives us the opportunity to deploy our iSTRYM technology, with the intended goal to optimize treatment for ATMA’s patients and obtain the data we need to build iSTRYM into the platform trusted by therapists and patients around the world.”
iSTRYM is an investigating technology that focuses on patient feedback and data-driven insights into the efficacy of treatments in order to assist in the application of more effective and more efficient diagnosis techniques and treatments. It’s a technology that is targeted for both therapists and patients.

As first stated in the LOI on January 12, 2021, MINDCURE’s investment into ATMA will facilitate the syndication of Mind Cure’s psychedelic drug protocols and the use of MINDCURE’s proprietary AI-driven platform, iSTRYM, to optimize treatment for ATMA clients.

“We are thrilled today to welcome a visionary leader like Kelsey to our Board of Directors,” said Vu Tran, Co-CEO of ATMA. “We are eager to get to work with the MINDCURE team to help establish the industry-standard protocols and digital tools to better help patients in need and the therapists that serve them.”

The strategic investment was comprised of a purchase of $350,000 of ATMA’s Series A Preference shares as part of ATMA’s Series A financing. MINDCURE satisfied the aggregate subscription price through the issuance of 796,541 common shares in its capital at an agreed-upon price of $0.4394 per share, being the 10-day volume-weighted average trading price of the common shares on the Canadian Securities Exchange.

About ATMA Journey Centers Inc.

ATMA is a private healthcare company with the mission of delivering effective and innovative healing and transformative experiences that awaken the inner healer and promote a deeper connection with the self, with others, and with the beauty of the world. ATMA was the first private sector service provider in Canada to announce conducting legal psychedelic-assisted therapy for a palliative care patient under the approval of Health Canada’s section 56(1) exemption. Our team members collectively have over 100 years of experience in the disciplines of medicine work, integration, therapy and personal development.

The ATMA Journey Team is comprised of medical professionals, management staff and advocates who believe that psychedelic and non-traditional medicines have an important role to play in the healing and transformation of humankind. We believe that the current approaches to mental and emotional struggles are simply not enough and that psychedelics hold the key to actually resolving the root causes of mental health issues that affect so many. The ATMA Team is deeply committed to creating and delivering the most effective long-term healing and transformation program available.

The Company has entered into an agreement with Psychedelic Finance to provide services relating to social media support and strategic media services for a six month term beginning in April, 2021. The Company has agreed to pay a total of CDN$60,000 for the services to be provided during the term.

About Mind Cure Health (MINDCURE) Inc.

MINDCURE exists as a response to the current mental health crisis and urgent calls for effective treatments. MINDCURE believes in the need to reinvent the mental health care model for patients and practitioners to allow psychedelics to advance into common and accepted care.

MINDCURE is focused on identifying and developing pathways and products that ease suffering, increase productivity, and enhance mental health. MINDCURE is interested in exploring diverse therapeutic areas beyond psychiatry, including digital therapeutics, neuro-supports, and psychedelics, all to improve mental health.

On Behalf of the Board of Directors
Kelsey Ramsden, President & CEO
Phone: 1-888-593-8995

Forward-Looking Information

Certain statements in this news release may constitute “forward-looking information” within the meaning of applicable securities laws (also known as forward-looking statements). Forward-looking information involves known and unknown risks, uncertainties and other factors, and may cause actual results, performance or achievements or industry results, to be materially different from any future results, performance or achievements or industry results expressed or implied by such forward-looking information. Forward-looking information generally can be identified by the use of terms and phrases such as “anticipate”, “believe”, “could”, “estimate”, “expect”, “feel”, “intend”, “may”, “plan”, “predict”, “project”, “subject to”, “will”, “would”, and similar terms and phrases, including references to assumptions. Some of the specific forward-looking information in this news release includes, but is not limited to, statements with respect to: MINDCURE deploying its iSTRYM technology through ATMA clinics; iSTRYM becoming the platform trusted by therapists and patients around the world; and ATMA and MINDCURE establishing the industry-standard protocols and digital tools to better help patients in need and the therapists that serve them.

Forward-looking information is based on a number of key expectations and assumptions made by MINDCURE, including, without limitation: the COVID-19 pandemic impact on the Canadian economy and MINDCURE’s business, and the extent and duration of such impact; no change to laws or regulations that negatively affect MINDCURE’s business; there will be a demand for MINDCURE’s products in the future; no unanticipated expenses or costs arise; MINDCURE will be able to continue to identify products that make them ideal candidates for providing solutions for treating mental health; that the functional mushroom industry will continue to grow; MINDCURE will deploy its iSTRYM technology through ATMA clinics; ATMA and MINDCURE  will establish the industry-standard protocols and digital tools to better help patients in need and the therapists that serve them; and MINDCURE will be able to operate its business as planned. Although the forward-looking information contained in this news release is based upon what MINDCURE believes to be reasonable assumptions, it cannot assure investors that actual results will be consistent with such information.

Forward-looking information is provided for the purpose of presenting information about management’s current expectations and plans relating to the future and readers are cautioned that such statements may not be appropriate for other purposes. Forward-looking information involves significant risks and uncertainties and should not be read as a guarantee of future performance or results as actual results may differ materially from those expressed or implied in such forward-looking information. Those risks and uncertainties include, among other things, risks related to: the impacts of the COVID-19 pandemic on the Canadian economy, MINDCURE’s industry and MINDCURE’s business, which may negatively impact, and may continue to negatively impact, MINDCURE and may materially adversely affect MINDCURE’s investments, results of operations, financial condition, and MINDCURE’s ability to obtain additional equity or debt financing, and satisfy its financial obligations; general economic conditions; future growth potential; competition for mental health and wellness investments MINDCURE may not deploy its iSTRYM technology through ATMA clinics; ATMA and MINDCURE  may not establish the industry-standard protocols and digital tools to better help patients in need and the therapists that serve them; and changes in legislation or regulations. Management believes that the expectations reflected in the forward-looking information contained herein are based upon reasonable assumptions and information currently available; however, management can give no assurance that actual results will be consistent with such forward-looking information. Additional information on the risk factors that could affect MINDCURE can be found under “Risk Factors” in MINDCURE’s final prospectus which is available on SEDAR at www.sedar.com.

The forward-looking information contained herein is expressly qualified in its entirety by this cautionary statement. Forward-looking information reflects management’s current beliefs and is based on information currently available to MINDCURE. The forward-looking information is stated as of the date of this news release and MINDCURE assumes no obligation to update or revise such information to reflect new events or circumstances, except as may be required by applicable law.

United States Advisory
The securities referred to herein have not been and will not be registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”), may be offered and sold outside the United States to eligible investors pursuant to Regulation S promulgated under the U.S. Securities Act, and may not be offered, sold, or resold in the United States or to, or for the account of or benefit of, a U.S. Person (as such term is defined in Regulation S under the United States Securities Act) unless the securities are registered under the U.S. Securities Act, or an exemption from the registration requirements of the U.S. Securities Act is available. Hedging transactions involving the securities must not be conducted unless in accordance with the U.S. Securities Act. This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in the state in the United States in which such offer, solicitation or sale would be unlawful.

The CSE has neither approved nor disapproved the contents of this press release and the CSE does not accept responsibility for the adequacy or accuracy of this release.

SOURCE Mind Cure Health Inc.

For further information: Investor Relations: investors@mindcure.com; 1-888-593-8995; Jonathan L. Robinson CFA, Partner, Oak Hill Financial Inc., jrobinson@oakhillfinancial.ca, 416-669-1001

‍

Posted on

New Wave Subsidiary, Way of Will Inc., Confirms Plans to Expand Brand Presence on Walmart.com

TORONTO, April 7, 2021 /CNW/ – NEW WAVE HOLDINGS CORP. (the “Company” or “New Wave”) (CSE: SPOR) (FWB: 0XM2) (OTCPK: TRMNF) an investment issuer that provides capital and support services, announced that it will set forth its plans to aggressively increase its brand presence on Walmart.com.

New Wave Holdings Logo (CNW Group/New Wave Holdings Corp.)
New Wave Holdings Logo (CNW Group/New Wave Holdings Corp.)

Way of Will, a growing health and wellness company known for its natural, aromatherapy-based products, will be putting its plans into motion to grow the brand’s presence on Walmart.com. The goal is to leverage online sales through the retail giant’s prominence as the second-largest e-commerce business in the U.S. by optimizing rich media content and partnering with a third-party logistics company to allow for two-day shipping via Walmart.com. Successful implementation of this strategic approach is expected to yield a 350% growth in online sales for Way of Will.

In order to ensure successful scalability on Walmart’s e-commerce platform, the natural wellness brand will be:

  • Partnering with leading RMC marketing agency, Seller Interactive, to produce rich media content for Walmart.com
  • Entering into an agreement with 3PL provider, Deliverr, to fulfill orders
  • Obtain Walmart’s Pro Seller Badge and make two-day delivery available for customers

“Based on our success the past year on Walmart.com, we’re looking forward to expanding our brand presence there, along with our product selection,” said Willie Tsang, founder and CEO of Way of Will. “Working with Deliverr will help us maximize efficiency and ensure that we keep up with the anticipated exponential sales growth on Walmart. We’re confident that, with the current growth strategy in place, we will be able to scale seamlessly and continue to see sales growth month over month.”

ABOUT NEW WAVE HOLDINGS CORP.

New Wave Holdings Corp. (CSE: SPOR, FWB: 0XM2, OTCPK: TRMNF) is an investment issuer focused on the burgeoning nutraceutical and psychedelic sector and support for adaptive and progressive health and wellness products and therapies. New Wave subsidiaries contain various health and beauty products within its portfolio of non-psychoactive plants and fungi as it continues to expand its product distribution through vertical integration to provide end to end solutions while capturing a high margin business model.

Investors interested in connecting with New Wave Holdings can learn more about the company and contact the team at http://newwavecorp.com.

Information relating to WAY OF WILL INC., contained in this news release was provided by WAY OF WILL INC. and/or its agent and has not been independently verified by the Company. The Company does not take responsibility for the accuracy of such information.

The CSE has not in any way passed on the merits of the Acquisition, and neither has approved nor disapproved the contents of this press release. Neither the CSE nor its Market Regulator (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.

FORWARD-LOOKING INFORMATION DISCLAIMER

Certain statements contained in this news release may constitute forward–looking information, including but not limited to, applicable regulatory approval in connection with the Acquisition, the closing of the Acquisition, expansion of operations, size and quality of future tournaments and projections regarding attendance at future events. Forward–looking information is often, but not always, identified by the use of words such as “anticipate”, “plan”, “estimate”, “expect”, “may”, “will”, “intend”, “should”, and similar expressions. Forward–looking information involves known and unknown risks, uncertainties and other factors that may cause actual results or events to differ materially from those anticipated in such forward–looking information. The Company’s actual results could differ materially from those anticipated in this forward–looking information as a result of competitive factors and competition for investment opportunities, challenges relating to operations in international markets, transaction execution risk, changes to the Company’s strategic growth plans, and other factors, many of which are beyond the control of the Company. The Company believes that the expectations reflected in the forward–looking information are reasonable based on current expectations and potential investment pipeline, but no assurance can be given that these expectations will prove to be correct and such forward–looking information should not be unduly relied upon. Any forward–looking information contained in this news release represents the Company’s expectations as of the date hereof and is subject to change after such date. The Company disclaims any intention or obligation to update or revise any forward–looking information whether as a result of new information, future events or otherwise, except as required by applicable securities legislation.

Cision
Cision

View original content to download multimedia:http://www.prnewswire.com/news-releases/new-wave-subsidiary-way-of-will-inc-confirms-plans-to-expand-brand-presence-on-walmartcom-301263994.html

SOURCE New Wave Holdings Corp.

Cision
Cision

View original content to download multimedia: http://www.newswire.ca/en/releases/archive/April2021/07/c3870.html

Posted on

MindMed Announces the Publication of New Data on Personalized MDMA Dosing

BASEL, Switzerland, April 5, 2021 /PRNewswire/ — MindMed (NEO: MMED) (OTCQB: MMEDF) (DE: MMQ), a leading clinical-stage psychedelic medicine biotech company, announced the publication of the first study on MDMA dosing optimization using personalized medicine. The study took place at the University Hospital Basel Liechti Lab, in Basel, Switzerland. This study provides the first scientific data for predicting responses to MDMA and optimizing dosing. This may maximize the potential beneficial therapeutic effects while reducing adverse responses when treating medical conditions.

The study used data from 194 MDMA administrations in ten randomized placebo-controlled studies in healthy subjects conducted by the Liechti Lab at the University Hospital Basel, Switzerland.

Key findings of the study suggest:

  • The dose of MDMA can be optimized using predictors known before dosing including body weight, sex, age, genetics, personality trait measures, and mood before drug administration.
  • The dose of MDMA per kg body weight of the treated person best predicted the MDMA concentrations in the body and also mainly determined the acute subjective response to MDMA.
  • Additionally, genetic testing of the drug metabolizing enzyme CYP2D6 is useful to adjust the dose of MDMA.
  • Persons with low levels of CYP2D6 activity have higher MDMA plasma concentrations and may experience greater subjective MDMA effects and may benefit from a moderate dose reduction.
  • Persons with a greater personality trait of “openness to a new experience” showed greater feelings of closeness and positive drug effects acutely induced by MDMA.
  • In contrast, persons with personality traits of increased neuroticism or anxiety were both more likely to experience fear of ego dissolution and losing control. Similarly, more feelings of anxiety and depression in a person just before MDMA administration predicted more anxiety after MDMA administration.
  • Women and men showed comparable MDMA effects if differences in body weight are considered in the dosing of MDMA.
  • Previous minimal MDMA use, defined as previously using MDMA up to five times, did not influence the MDMA effect.
  • In summary, personalizing MDMA dosing may help optimize the acute MDMA experience including more positive subjective effects of MDMA and reducing adverse effects of MDMA.

The study was published in the Journal of Psychopharmacology and the full-text can be accessed from the publishers at: https://journals.sagepub.com/doi/full/10.1177/0269881121998322

Dr. Matthias Liechti said, “To our knowledge, this is the first study on personalized MDMA treatment including pharmacogenetics, personality assessments, and psychometrics in one analysis. The method used allowed us to evaluate the relative importance of the different predictors. Very clearly, the dose of MDMA has the greatest impact on the acute subjective response. However, genetics, personality, and mood before MDMA use also moderated the response to MDMA use. Importantly, the data was obtained in studies using a safe hospital environment and in younger healthy volunteers with mostly no past MDMA experience. Additional data in patients is needed.”

MindMed Executive President, Dr. Miri Halperin Wernli said, “With the promise of advances in psychedelic medicine we are aiming to step away from the rather rigid and inflexible drug centric approach of ‘one size fits all’ and start leveraging data and machine learning to help health professionals and patients engage new personalized therapies in the treatment paradigms. We are building unique biomarker profiles of individuals across genetics, phenotypes, personality traits, and cognitive states that will allow us to best predict which therapy framework configurations will be most effective. The analysis will also include set and setting related variables, therapy, post-therapy integration, and longitudinal follow-ups. Our work focuses on applying the concepts of personalized medicine, AI, and cross disciplinary cutting-edge research to better understand and predict how individual biological phenotypes, genetics, and mental states correlate and interact with responses to the new psychedelic intervention paradigms. We hope this will enable us to build and offer better decision support systems for healthcare professionals and their patients, delivering the best set of evidence and scientifically derived therapy framework options for mental health treatment.”

About MindMed

MindMed is a clinical-stage psychedelic medicine biotech company that discovers, develops and deploys psychedelic inspired medicines and therapies to address addiction and mental illness. The company is assembling a compelling drug development pipeline of innovative treatments based on psychedelic substances including Psilocybin, LSD, MDMA, DMT and an Ibogaine derivative, 18-MC. The MindMed executive team brings extensive biopharmaceutical experience to MindMed’s approach to developing the next generation of psychedelic inspired medicines and therapies.

MindMed trades on the Canadian exchange NEO under the symbol MMED. MindMed is also traded in the United States under the symbol MMEDF and in Germany under the symbol MMQ.

Forward-Looking Statements

Certain statements in this news release related to the Company constitute “forward-looking information” within the meaning of applicable securities laws and are prospective in nature. Forward-looking information is not based on historical facts, but rather on current expectations and projections about future events and are therefore subject to risks and uncertainties which could cause actual results to differ materially from the future results expressed or implied by the forward-looking statements. These statements generally can be identified by the use of forward-looking words such as “will”, “may”, “should”, “could”, “intend”, “estimate”, “plan”, “anticipate”, “expect”, “believe”, “potential” or “continue”, or the negative thereof or similar variations. Forward-looking information in this news release include statements regarding our ability to predict which therapy framework configurations will be most effective, the use of personalized medicine, AI, and cross disciplinary cutting-edge research to understand and predict how individual biological phenotypes, genetics, and mental states correlate and interact with responses to new psychedelic intervention paradigms, our ability to build and offer better decision support systems for healthcare professionals and their patients, our delivery of evidence and scientifically derived therapy framework options for mental health treatment, the pursuit of strategic initiatives, and the Company’s intended future business plans and operations, including the development of psychedelic inspired medicines and experiential therapies. Although the Company believes that the expectations reflected in such forward-looking information are reasonable, such information involves risks and uncertainties, and undue reliance should not be placed on such information, as unknown or unpredictable factors could have material adverse effects on future results, performance or achievements of the Company. There are numerous risks and uncertainties that could cause actual results and the Company’s plans and objectives to differ materially from those expressed in the forward-looking information, including history of negative cash flows; limited operating history; incurrence of future losses; availability of additional capital; lack of product revenue; compliance with laws and regulations; difficulty associated with research and development; risks associated with clinical trials or studies; heightened regulatory scrutiny; early stage product development; clinical trial risks; regulatory approval processes; novelty of the psychedelic inspired medicines industry; as well as those risk factors discussed or referred to herein and the risks described under the headings “Risk Factors” in the Company’s filings with the securities regulatory authorities in all provinces and territories of Canada which are  available under the Company’s profile on SEDAR at www.sedar.com with the U.S. Securities and Exchange Commission on EDGAR at www.sec.gov. Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking information prove incorrect, actual results and future events could differ materially from those anticipated in such information. Although the Company has attempted to identify important risks, uncertainties and factors that could cause actual results to differ materially, there may be others that cause results not to be as anticipated, estimated or intended. These and all subsequent written and oral forward-looking information are based on estimates and opinions of management on the dates they are made and are expressly qualified in their entirety by this notice. Except as required by law, the Company does not intend and does not assume any obligation to update this forward-looking information.

Posted on

Bioprocessing Psilocybin for Mental Health

Psilocybin mushrooms make tryptamines, which are responsible for their hallucinogenic effects, but also can be used to treat various mental-health conditions, from anxiety to PTSD.

At the Miami University in Ohio, J. Andrew Jones, PhD, assistant professor in the department of chemical, paper, and biomedical engineering, and his students have developed a new way to make these chemicals. PsyBio Therapeutics, where Jones is chairman of the scientific advisory board, is commercializing the process.

Jones and his team invented a one-pot method of bioprocessing with E. coli to make tryptamines. Starting with 4-hydroxyindole, the process developed by Jones produces psilocybin. He says that this technique provides three key advantages—cheaper, faster, and greener than other methods.

J. Andrew Jones, PhD [PsyBio Therapeutics]

Compared to chemical synthesis, for example, Jones points out that his method “does not require a lot of expensive reagents or multiple purification steps and produces much higher yields—about three times higher.” Plus, it only takes about four days of fermentation, which is twice as fast as synthesizing the compounds with yeast.

And lastly, the method created by Jones does not require the toxic reagents, such as palladium catalysts and hydride reducing agents required by other methods, making it overall a greener process.

Beyond these features, the technique that Jones created offers flexibility, making it easier to modify products. “We can quickly develop an optimized host using the right balance of genetic elements,” Jones explains. “So, our platform is fast in bioprocessing and also in strain development.”

Posted on

AIkido Pharma Provides Business Update

Well-Capitalized to Further Efforts and Opportunistically Expand Portfolio

Drug Research and Development Progressing

Well-Capitalized to Further Efforts and Opportunistically Expand Portfolio

PR Newswire

NEW YORK , April 5, 2021 /PRNewswire/ — AIkido Pharma Inc. (Nasdaq: AIKI) (“AIkido” or the “Company”) today provided a business update.

(PRNewsfoto/AIkido Pharma Incorporated)

Anthony Hayes , CEO of AIkido Pharma, stated, “AIkido’s primary focus is the commercialization of improved treatments for multiple types of cancer and viral infections through innovative research and development that leverages the power of artificial intelligence and machine learning. Our research partners continue to make progress towards this focus with positive results in ongoing preclinical studies. In addition, through a series of financing transactions over the course of 2020, and the last several months, we are sufficiently capitalized to support our current efforts and to pursue additional emerging opportunities to further broaden our portfolio.”

Drug Research and Development

The Company continues its work to develop therapeutic drug compounds through strong partnerships with prominent educational institutions, including the University of Texas at Austin and the University of Maryland at Baltimore , and is constantly seeking to grow its pipeline of treatments in oncology through additional licensing opportunities. The Company’s business portfolio, which is initially focused on the treatment of cancer and multiple types of viral infections with drug candidates in varying stages of research and development, includes a diverse mix of small-molecule anticancer and antiviral therapeutics.

Most recently, the Company committed to sponsoring psychedelic research at the Mount Sinai Center for Psychedelic Psychotherapy and Trauma Research to help veterans who are suffering from post-traumatic stress disorder (PTSD) and other trauma-related symptoms. The Center will conduct clinical trials to identify biomarkers that predict and correlate with positive treatment outcomes by analyzing blood samples and performing neuroimaging tests before and after therapy. Applications in the treatment of PTSD represent a tremendous opportunity with nearly nine million people in the U.S. struggling with the disorder annually.

The Company’s broad spectrum anti-viral platform has shown progress in optimizing drugs for the treatment of influenza, COVID-19, Ebola and other viral infections. The initial two lead compounds have been optimized using computer assisted learning through two rounds of chemical modifications to achieve drug-like properties required to move the compounds into animal testing. In addition, a third lead compound has been identified and will be subjected to computer assisted optimization. These new compounds are being tested against influenza virus with testing on SARS-CoV-2 expected in the near future. Subsequently, the top analogs from each series of lead compounds will be selected for tests of their anti-viral effects in a SARS-CoV-2 mouse model.

In January of this year, the Company acquired an ownership interest in Convergent Therapeutics, Inc., which has exclusive rights to technology related to next-generation dual-action peptide receptor radionuclide therapy (“PRRT”) for prostate cancer covered by multiple issued U.S. and foreign patents. Convergent is currently conducting advanced human trials relating to prostate cancer treatments utilizing PRRT that targets the prostate-specific membrane antigen (“PSMA”) present on prostate cancer cells. The technology was developed under the direction of Dr. Neil Bander, Professor of Urologic Oncology at Weill Cornell Medicine.  Phase 1 data is projected to be released in Q2 of 2021

Also, after year end, the Company executed an exclusive patent license agreement with Silo Pharma, Inc. (“Silo Pharma”) for technology that covers the use of psilocybin for cancer patients.  Importantly, this license provides the Company with the opportunity to explore an emerging and expanding treatment for neuroinflammation, which is frequently associated with cancer, and other cancer-related neurological side-effects. The technology is covered by four patent applications already on file with the United States Patent and Trademark Office.

Capital Resources

Subsequent to year end, the Company raised nearly $90 million , before discounts, commissions and estimated expenses, to support its investigative and preclinical work as well as pursue strategic investment opportunities as they arise. As such, the Company is constantly seeking to grow its pipeline of treatments in oncology. With approximately $25 million in cash and cash equivalents at year end and the additional boost from recent offerings, the Company has extended its runway for further investment in drug development. The Company utilized cash from operations in 2020 of just over $4.0 million .

Corporate Governance

The Company reinforced its corporate governance with the appointment of two new independent directors, Mr. Paul LeMire and Mr. Robert Dudley , who each bring extensive executive experience as well as decades of financial expertise in overseeing the Company’s execution of its strategy and financing of operations.

In addition, the Company strengthened its Scientific Advisory Board with the addition of two new advisors, Dr. Scott T. Tagawa , M.D. and Inventor Dr. Neil H. Bander, M.D., who are each widely respected leaders in their respective fields. They bring a wealth of experience and expertise to the Company’s efforts to advance the research and development of commercially viable drug therapies.

About AIkido Pharma Inc.

AIkido Pharma Inc. was initially formed in 1967 and is a biotechnology Company with a diverse portfolio of small-molecule anti-cancer therapeutics.  The Company’s platform consists of patented technology from leading universities and researchers and we are currently in the process of developing an innovative therapeutic drug platform through strong partnerships with world renowned educational institutions, including The University of Texas at Austin and University of Maryland at Baltimore . Our diverse pipeline of therapeutics includes therapies for pancreatic cancer and prostate cancer. We are constantly seeking to grow our pipeline to treat unmet medical needs in oncology.  The Company is also developing a broad-spectrum antiviral platform that may potentially inhibit replication of multiple viruses including Influenza virus, SARS-CoV (coronavirus), MERS-CoV, Ebolavirus and Marburg virus.

Forward-Looking Statements

Certain statements in this press release constitute “forward-looking statements” within the meaning of the federal securities laws. Words such as “may,” “might,” “will,” “should,” “believe,” “expect,” “anticipate,” “estimate,” “continue,” “predict,” “forecast,” “project,” “plan,” “intend” or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. While the Company believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward-looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties, including without limitation those set forth in the Company’s filings with the SEC, not limited to Risk Factors relating to its business contained therein. Thus, actual results could be materially different. The Company expressly disclaims any obligation to update or alter statements whether as a result of new information, future events or otherwise, except as required by law.

Contact:

Investor Relations:

Hayden IR
Brett Maas , Managing Partner
Phone: (646) 536-7331
Email: brett@haydenir.com
www.haydenir.com

AIkido Pharma Inc.:

Phone: 212-745-1373
Email: investorrelations@aikidopharma.com
www.aikidopharma.com

CisionView original content to download multimedia: http://www.prnewswire.com/news-releases/aikido-pharma-provides-business-update-301261423.html

SOURCE AIkido Pharma Inc.

News Provided by PR Newswire via QuoteMedia

Posted on

New Wave Subsidiary, Way of Will Inc., Announces Plans to Expand Brand Presence on Amazon US and Canada

TORONTO, April 1, 2021 /CNW/ – NEW WAVE HOLDINGS CORP. (the “Company” or “New Wave”) (CSE: SPOR) (FWB: 0XM2) (OTCPK: TRMNF) an investment issuer that provides capital and support services, today announced its plans to expand Way of Will’s brand presence on the e-commerce giant, Amazon.

New Wave Holdings Corp. (CNW Group/New Wave Holdings Corp.)
New Wave Holdings Corp. (CNW Group/New Wave Holdings Corp.)

Way of Will, a health and wellness brand offering a large assortment of natural skin care and body care, is in preparation of listing to widen our selection on the Amazon US and Canada platform at the beginning of May this year. This preparation incudes:

  • Creative assets for listings
  • Data analytics including search demands
  • Competitive analysis
  • Keywords and product optimization
  • Inventory fulfillments to FBA

Once the majority of the brand’s collection are added to the e-commerce platform, the company is expected to see a growth of 20% in revenue. The goal of increasing the selection of products on Amazon is to optimize sales and fortify the company’s growth strategy.

Products that are currently available on Amazon include Way of Will’s popular massage oil, deodorants, face mask sprays, nail serum, and their Athletic Collection skin-care products. New products that customers can expect to find on Amazon starting in May will include bestsellers such as hand washes, hand & body lotions, hydrating face spray, and face oil serums. Amazon US customers will also be able to purchase mushroom capsules and mushroom powder, which are a part of Way of Will’s new collection of Functional Mushroom products.

The health and wellness brand is widely loved for offering products that are cruelty-free, incorporating all-natural ingredients that are genuinely good for the skin, and eliminating harsh ingredients from their formulations found in conventional skin-care products. In the past year, the company has also made a commitment to move toward more eco-friendly packaging for a more environmentally responsible approach to their business.

“We’re thrilled to be adding almost our entire assortment of products to both Amazon US and Amazon Canada,” commented Willie Tsang, founder and CEO of Way of Will. “The existing products that we’ve had on Amazon for the past years have been well-received, so we’re confident that the new products will be a welcoming addition to our selection. Our goal is to maximize sales by diversifying our sales channels and gain more exposure on different platforms, so we can have a greater reach and prevent dependency on any one channel.”

ABOUT NEW WAVE HOLDINGS CORP.

New Wave Holdings Corp. (CSE: SPOR, FWB: 0XM2, OTCPK: TRMNF) is an investment issuer focused on the burgeoning nutraceutical and psychedelic sector and support for adaptive and progressive health and wellness products and therapies. New Wave subsidiaries contain various health and beauty products within its portfolio of non-psychoactive plants and fungi as it continues to expand its product distribution through vertical integration to provide end to end solutions while capturing a high margin business model.

Investors interested in connecting with New Wave Holdings can learn more about the company and contact the team at http://newwavecorp.com.

Information relating to WAY OF WILL INC., contained in this news release was provided by WAY OF WILL INC. and/or its agent and has not been independently verified by the Company. The Company does not take responsibility for the accuracy of such information.

The CSE has not in any way passed on the merits of the Acquisition, and neither has approved nor disapproved the contents of this press release. Neither the CSE nor its Market Regulator (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.

FORWARD-LOOKING INFORMATION DISCLAIMER

Certain statements contained in this news release may constitute forward–looking information, including but not limited to, applicable regulatory approval in connection with the Acquisition, the closing of the Acquisition, expansion of operations, size and quality of future tournaments and projections regarding attendance at future events. Forward–looking information is often, but not always, identified by the use of words such as “anticipate”, “plan”, “estimate”, “expect”, “may”, “will”, “intend”, “should”, and similar expressions. Forward–looking information involves known and unknown risks, uncertainties and other factors that may cause actual results or events to differ materially from those anticipated in such forward–looking information. The Company’s actual results could differ materially from those anticipated in this forward–looking information as a result of competitive factors and competition for investment opportunities, challenges relating to operations in international markets, transaction execution risk, changes to the Company’s strategic growth plans, and other factors, many of which are beyond the control of the Company. The Company believes that the expectations reflected in the forward–looking information are reasonable based on current expectations and potential investment pipeline, but no assurance can be given that these expectations will prove to be correct and such forward–looking information should not be unduly relied upon. Any forward–looking information contained in this news release represents the Company’s expectations as of the date hereof and is subject to change after such date. The Company disclaims any intention or obligation to update or revise any forward–looking information whether as a result of new information, future events or otherwise, except as required by applicable securities legislation.

Cision
Cision

View original content to download multimedia:http://www.prnewswire.com/news-releases/new-wave-subsidiary-way-of-will-inc-announces-plans-to-expand-brand-presence-on-amazon-us-and-canada-301260691.html

SOURCE New Wave Holdings Corp.

Cision
Cision

View original content to download multimedia: http://www.newswire.ca/en/releases/archive/April2021/01/c3703.html

Posted on

Delic Subsidiary Complex Biotech Discovery Ventures Ltd., Receives First Research Orders

After recently launching its Advanced Analytical Testing services, CBDV successfully receives orders through their new online payment platform 

VANCOUVER, BC, March 31, 2021 /PRNewswire/ –  Delic Holdings Inc. (the “Company”), (“DELIC”) (CSE: DELC) (OTCQB: DELCF), a psychedelic focused wellness company, is pleased to announce that its acquisition target, Complex Biotech Discovery Ventures Ltd. (“CBDV”), a licensed cannabis and psilocybin research laboratory specializing in chemical analytics, extraction optimization, and process design, has commercialized and received its first research orders for Advanced Analytical Testing services through CBDV’s new online payment platform.

Matt Stang, CEO and Co founder commented “CBDV has shown they have the foresight to see what is needed in industries before it is normal practice. We expect to see the same professional expertise they show in cannabis, in this new psychedelic industry. This is another milestone that shows our commitment to increasing shareholder value.”

CBDV recently launched its Advanced Analytical Testing service which offers a streamlined process that allows clients to conveniently order tests online and ship their samples directly to CBDV’s lab. Clients can choose from a wide range of tests that provide a comprehensive analysis on cannabis flower, concentrates, formulations, and vapor/smoke.

Chief Executive Officer, Dr. Markus Roggen, stated: “We saw the need for chemical analytics beyond compliant testing to enable producers to develop the next generation of cannabis products. Therefore, we wanted to bring the high precision tools we are using in our own research directly to Canadian producers. And to enable an efficient customer experience, while giving us a scalable platform, we put a lot of effort into this webstore.”

With access to facilities at the University of British Columbia, CBDV uses industry-leading instrumentation and chemical expertise to provide clients with a thorough analysis of their cannabis samples. Clients receive an in-depth and precise characterization of their materials throughout each stage of the product development process. The tests offered go beyond the basic compliance testing for product releases required by Health Canada. CBDV’s variety of tests include smoke analysis, NMR spectroscopy, X-ray crystallography, high resolution mass spectroscopy and many more that can be ordered directly on CBDV’s website.

For more information on the transaction between the Company and CBDV, please refer to the news release of the Company dated February 25, 2021.

About CBDV

Complex Biotech Discovery Ventures (CBDV), based at the University of British Columbia in Vancouver, BC, is a licensed cannabis and psilocybin research laboratory focused on extraction optimization, analytical testing, and process development. Founded by award-winning chemists, Dr. Markus Roggen and UBC Professor Glenn Sammis, CBDV uses precision chemical analytics and metabolomics identification to advance the cannabis and psilocybin industries.

For media and service inquiries, please contact info@cbdvl.com. Learn more at www.cbdvl.com and follow us on LinkedIn: Complex Biotech Discovery Ventures and Instagram: @complexbiotech.

About DELIC

DELIC Always Expanding. In All Ways.

DELIC was formed in 2019 to address the growing interest in psychedelic wellness backed by science. DELIC was the ‎first psychedelic umbrella platform and is currently a trusted source for those interested in ‎psychedelic culture, psychedelic clinics, and more. ‎DELIC’s offerings include, Ketamine Infusion Center (under binding acquisition agreement), a limited liability corporation formed under the laws of Arizona and runs two ketamine clinics in Arizona and California, “Reality Sandwich”, a free public education platform providing psychedelic guides, news and ‎culture, “Meet Delic”, the first ever psychedelic wellness summit, and “The Delic”, an e-commerce lifestyle brand. ‎For more information, check out www.deliccorp.com.

The Canadian Securities Exchange ‎has neither approved nor disapproved the contents of this news release and does not accept responsibility ‎for the adequacy or accuracy of this release.‎

Forward-Looking Information and Statements

This press release contains certain “forward-looking information” within the meaning of applicable ‎Canadian securities ‎legislation and may also contain statements that may constitute “forward-looking ‎statements” within the meaning of ‎the safe harbor provisions of the United States Private Securities ‎Litigation Reform Act of 1995. Such forward-looking ‎information and forward-looking statements are not ‎representative of historical facts or information or current ‎condition, but instead represent only the ‎Company’s beliefs regarding future events, plans or objectives, many of ‎which, by their nature, are ‎inherently uncertain and outside of DELIC’s control. Generally, such forward-looking ‎information or ‎forward-looking statements can be identified by the use of forward-looking terminology such as ‎‎”plans”, ‎‎”expects” or “does not expect”, “is expected”, “budget”, “scheduled”, “estimates”, “forecasts”, “intends”, ‎‎‎”anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or may ‎contain ‎statements that certain actions, events or results “may”, “could”, “would”, “might” or “will be ‎taken”, “will continue”, ‎‎”will occur” or “will be achieved”. The forward-looking information and forward-‎looking statements contained herein ‎may include, but are not limited to, closing of the transaction with CBDV (the “Transaction”), the growth and business of CBDV, potential earn out payments, anticipated continued growth in the health and wellness sector (and, in particular, related to psychedelics), the continued emergence of psychedelics from stigmas, the ability of the Company to maintain sensible messaging, the ability of the Company to avoid dogmatic practices and binary rhetoric‎, the ability of DELIC to successfully achieve business ‎objectives, ‎and expectations ‎for other economic, ‎business, and/or competitive factors.‎

By identifying such information and statements in this manner, DELIC is alerting the reader that ‎such ‎information and statements are subject to known and unknown risks, uncertainties and other factors ‎that may cause ‎the actual results, level of activity, performance or achievements of DELIC to be ‎materially different from those ‎expressed or implied by such information and statements. In addition, in ‎connection with the forward-looking ‎information and forward-looking statements contained in this press ‎release, DELIC has made certain ‎assumptions. Among the key factors that could cause actual ‎results to differ materially from those projected in the ‎forward-looking information and statements are the ‎following:‎ the ability to consummate the Transaction; the ability to satisfy the conditions to closing of the Transaction on the proposed terms and schedule; the potential impact of the announcement or consummation of the acquisition on ‎relationships, ‎including with regulatory bodies, employees, suppliers, customers and competitors; ‎changes in general economic, ‎business and political conditions, including changes in the financial ‎markets; changes in applicable laws; compliance ‎with extensive government regulation; and the diversion of management time on the Transaction.

Should one or more of these risks, uncertainties or other factors materialize, or should assumptions ‎underlying the ‎forward-looking information or statements prove incorrect, actual results may vary ‎materially from those described ‎herein as intended, planned, anticipated, believed, estimated or ‎expected.‎

Although DELIC believes that the assumptions and factors used in preparing, and the expectations ‎contained ‎in, the forward-looking information and statements are reasonable, undue reliance should not ‎be placed on such ‎information and statements, and no assurance or guarantee can be given that such ‎forward-looking information and ‎statements will prove to be accurate, as actual results and future events ‎could differ materially from those anticipated ‎in such information and statements. The forward-looking ‎information and forward-looking statements contained in this ‎press release are made as of the date of ‎this press release, and DELIC does not undertake to update any ‎forward-looking information ‎and/or forward-looking statements that are contained or referenced herein, except in ‎accordance with ‎applicable securities laws. All subsequent written and oral forward- looking information and ‎statements ‎attributable to DELIC or persons acting on its behalf is expressly qualified in its entirety by this ‎‎notice.‎